UPMC Hillman Cancer Center | Strategic Alliance Partners

February 24, 2023

Yvonne Chao, MD, PhD, discusses the study of various PD-L1 inhibitors in patients with non–small cell lung cancer.

February 02, 2023

Timothy Burns, MD, PhD, discusses the evolution of EGFR-targeted non–small cell lung cancer treatments, the importance of delineating small cell lung cancer subtypes, and the advantages of continued antibody-drug conjugate development across all areas of lung cancer.

November 28, 2022

The combination of the p38 MAPK inhibitor ARRY-614 plus nivolumab with or without ipilimumab was well tolerated and elicited disease control in high-risk, PD-(L)1–refractory patients with advanced solid tumors.

October 13, 2022

A new study pinpoints how LAG3 modulates T cell activity, providing important insights for development of other LAG3-blocking therapies for cancer and autoimmune disorders.

June 05, 2022

Treatment with lisocabtagene maraleucel resulted in a high rate of durable overall and complete responses as second-line therapy in frail patients with relapsed/refractory large B-cell lymphoma for whom hematopoietic stem cell transplantation was not intended, according to preliminary findings from the phase 2 PILOT study.

May 27, 2022

Present in approximately two-thirds of estrogen receptor-positive breast cancers, the role of ESR1 mutations in disease metastasis is poorly defined.

May 18, 2022

Adam M. Brufsky, MD, PhD, emphasizes the importance of tyrosine kinase inhibitors in HER2-postive breast cancer and highlights the potential benefits of local salvage radiation therapy in patients with oligometastatic or de novo stage IV breast cancer.

April 29, 2022

Alexander B. Olawaiye, MD, discusses how to address disparities in cancer care.

April 26, 2022

John M. Kirkwood, MD, discusses the utilization of ipilimumab and nivolumab in patients with melanoma with brain metastases.

April 19, 2022

Jason Luke, MD, FACP, reviews key points from each presentation from an Institutional Perspectives in Cancer webinar on melanoma and provides perspective on the practice-changing benefits of therapies moving into earlier lines of treatment.

March 21, 2022

Alexander B. Olawaiye, MD, discusses how social and biological determinants can affect care outcomes across cancer subtypes and what steps community and academic oncologists can take to ensure these disparities are recognized.

March 15, 2022

Alexander B. Olawaiye, MD, discusses front line treatment sequencing considerations in ovarian cancer.

March 14, 2022

Alexander Babatunde Olawaiye, MD, discusses frontline and second-line maintenance in ovarian cancer, the role of surgery in platinum-sensitive disease, and updates in cervical and endometrial cancers.

March 12, 2022

Alexander B. Olawaiye, MD, discusses the social and biological determinants of disparities in women’s cancer.

February 01, 2022

Alexander Babatunde Olawaiye, MD, discusses the investigation of balstilimab plus zalifrelimab in gynecologic cancers.

January 17, 2022

Adam M. Brufsky, MD, PhD, FACP, discusses the significance of the data from DESTINY-Breast03 with trastuzumab deruxtecan vs T-DM1 for patients with metastatic HER2-positive breast cancer, as well as how the findings set the field up to improve outcomes for patients with brain metastases.

January 14, 2022

Robert L. Ferris, MD, PhD, discusses the current standard of care for patients with head and neck cancer, the role of HPV in treatment decisions, and the need to personalize therapy for patients.

January 12, 2022

Adam M. Brufsky, MD, PhD, FACP, discusses the unique mechanism of action of zanidatamab and encouraging efficacy observed in patients with HER2-positive breast cancer.

January 03, 2022

Adam M. Brufsky, MD, PhD, FACP, discusses the rationale to evaluate enobosarm in estrogen receptor–positive, androgen receptor–positive metastatic breast cancer, prior data observed with the agent, and the unmet needs positive results of the ARTEST trial could potentially fulfill.

December 23, 2021

Adam M. Brufsky, MD, PhD, FACP, discusses the rationale to evaluate HER2-directed bispecific antibodies in HER2-positive breast cancer, the emergence of zanidatamab as a potential treatment strategy, and the unmet medical need the agent could fill in this disease.